key: cord-0301060-p46txjbo authors: Nusaïbah Ibrahimi, Agnès Delaunay-Moisan; Catherine Hill, Gwénaël Le Teuff; Jean-François Rupprecht, Jean-Yves Thuret; Dan Chaltiel, Marie-Claude Potier title: Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab? Systematic review and meta-analysis date: 2021-02-12 journal: nan DOI: 10.1101/2021.02.10.21251508 sha: f9129d220ce5a9927e948d427b3b1c3c41c65d9c doc_id: 301060 cord_uid: p46txjbo nan Why was this study done? Three published meta-analysis comparing SARS-CoV-2 loads in paired saliva and nasopharyngeal samples included only 4, 5 and 16 studies up to December 29th, 2020. We thus searched additional studies in PubMed with the key words "((SARS-CoV-2 OR COVID-19) AND (saliva OR oral fluid)) NOT (review[Publication Type])" applying the following criteria: records published in peer reviewed scientific journals, in English, with at least 15 saliva and nasopharyngeal/orapharyngeal paired samples tested by RT-PCR, studies with available raw data including numbers of positive and negative tests with the two sampling methods. What did the researchers do and find? Forty-nine published studies were eligible, reporting on 16,272 pairs of saliva and nasopharyngeal/oropharyngeal samples. Our unprecedented meta-analysis showed high concordance (92.6%) across studies and pooled sensitivities of 86.7% and 92.2% from saliva and nasopharyngeal/oropharyngeal swabs respectively. What do these findings mean? Sensitivity of SARS-CoV-2 RT-PCR detection in saliva samples is above the 80% sensitivity cut-off recommended by health regulatory authorities. Our meta-analysis validates the use of saliva sample for mass screening to combat the COVID-19 pandemic. Propagation of infections by SARS-CoV-2, the coronavirus causing the COVID-19 pandemic, occurs from asymptomatic as well as symptomatic carriers 1 . To reduce the circulation of the virus in the population, SARS-CoV-2 carriers need to be identified rapidly and isolated as soon as possible, ideally before the onset of symptoms. When the virus has disseminated throughout a whole country, massive testing becomes of utmost urgent importance to combat the pandemic [2] [3] [4] . To make the diagnostic acceptable to the greatest number of people, especially asymptomatic, massive testing should be based on a sampling procedure that is inexpensive, easy to set up and well accepted by the population 9 . In contrast to nasopharyngeal swabbing, saliva sampling meets these criteria. Saliva sampling is fast, non-invasive, inexpensive and painless. It does not require trained professional and personal protective equipment nor other material than simple plastic tube, and can be self-administered. To evaluate saliva sampling for the detection of SARS-CoV-2, we conducted a meta-analysis on studies published in peer-reviewed journals until the 29 th of December 2020 comparing the detection of SARS-CoV-2 using RT-PCR on paired nasopharyngeal/oropharyngeal and saliva samples in the same individuals sampled at the same time. Literature search in PubMed (https://pubmed-ncbi-nlm-nih-gov) run the 29 th of December 2020 with search word ((SARS-CoV-2 OR COVID-19) AND (saliva OR oral fluid)) NOT (review[Publication Type]) identified 315 articles. We included publications if they met the following eligibility criteria: . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint 1) Records published in peer reviewed scientific journals; 2) Records published in English; 3) Data curation based on examination of the titles and abstract, searching for research articles assessing viral RNA presence in saliva vs nasopharyngeal and/or oropharyngeal swabs; 4) Availability of nasopharyngeal (and/or oropharyngeal) swabs and saliva data on specimens sampled on the same individuals at the same time; 5) Detection of SARS-CoV-2 using the same RT-PCR method on both samples; 6) More than 15 individuals included in the study. From each eligible article, we extracted: the number of individuals positive for SARS-CoV-2 in both nasopharyngeal/oropharyngeal swabs and saliva (a), those positive only in nasopharyngeal/oropharyngeal swab (b), those positive only in saliva (c) and (d) those negative in both nasopharyngeal swab and saliva ( Table 1) . All articles where we highlighted the extracted data are available on the following link 10 . From these data, we calculated the concordance of the same test (RTqPCR for 48 studies and RTdPCR for 1 study) on the two types of sample (a+d)/(a+b+c+d). We also computed the sensitivity of the test on each type of sample. The estimation of the sensitivity of a test requires a reference diagnosis. Since nasopharyngeal swab sampling has been shown to produce false negatives by RTqPCR 11 , sensitivities for the saliva and the nasopharyngeal swab The overall concordance and sensitivities have been estimated in a meta-analysis via Generalized Linear Mixed Models (GLMM) 12,13 , using a fixed-effect model, and also a random-effect model in case of an over dispersion of the observations. Dispersion of effect sizes was evaluated using the Higgins I 2 estimate of heterogeneity along with the Cochran's Q in fixed-effect models 14 and using the tau² estimate (between-study variance which is the variance of the distribution of true effect size) in random-effects models. The tau² was calculated using the maximum likelihood estimator. As some studies have a sample size too small for the normality hypothesis, confidence intervals for each study were computed using the Clopper-Pearson method 15 also called "exact" binomial interval. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint Those for the overall estimates are based on normal approximation. Results are presented as forest plots. All analyses were done with R version 4.0.3, using the package "meta" version 4.15-1 (2020-09-30) 16,17 . (Figure 4) . There was no association between the sensitivities of the saliva ( Figure S1 ) or of nasopharyngeal swab ( Figure S2 ) estimated in each study and the prevalence of the virus in the same study. If the sensitivity of the saliva was lower in populations of asymptomatic individuals than in population of individuals with symptoms, one would expect to observe a lower sensibility of the saliva in the studies with a low prevalence. In our fixed-effect model meta-analysis, saliva gave I² of 80% and nasopharyngeal gave I² of 84%, both corresponding to high heterogeneity. Therefore, a random-effect model was performed to assess the overall sensitivities of the RTqPCR tests, taking into account the fact that the studies do not came from one single population. The variance of saliva was 0.51 and that of nasopharyngeal was 1.02. As a sensitivity analysis, we also used various other methods to estimate the sensitivity, the confidence interval and the tau² and all yielded very similar results. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint This meta-analysis reviewed 49 studies and concluded to a high concordance between nasopharyngeal and saliva samples for the detection of SARS-CoV-2 by RT-PCR. Although sensitivity was slightly lower on saliva samples than on nasopharyngeal samples, both values are above the 80% sensitivity cut-off recommended by health regulatory authorities such as the French Haute Autorité de Santé. For computing concordance and sensitivities, we considered here the reference as SARS-CoV-2 positivity by RT-PCR either in saliva and/or nasopharyngeal samples since the presence of the virus in any sample is indicative of virus carriage. In the context of mass screening, most participants are asymptomatic. Among the 49 studies analysed, only one included exclusively asymptomatic participants 67 and 8 studies both symptomatic and asymptomatic participants but it was impossible to separate the data between the two populations 18,21,26,29,51,56,64,66 . One study of contact cases included a larger number of asymptomatic subjects as compared to study of symptomatic subjects 49 . We did not observe any difference in concordance of the tests in these particular studies involving asymptomatic participants ( Table 1) . Formal comparison of nasopharyngeal and saliva samples from asymptomatic individuals is challenging: it would require to screen a large population for a small number of positive cases detected since the prevalence is usually low in this population. On the contrary, the symptomatic population expectedly contains higher percentage of positive subjects, as symptoms usually timely correlates with the highest viral load, which allow an easier comparison of both sampling procedures. Anyhow viral load in saliva of presymptomatic subjects remains in the range of detection of the RTqPCR test for several days both in saliva 68 and nasopharyngeal samples 69 . In addition, both asymptomatic and symptomatic subjects appear to be contagious 1 with similarities in their viral load evolution [70] [71] [72] . Moreover, Figure S3 shows that in France the proportion of positive cases in the symptomatic tested population is consistently about 5 times that of the asymptomatic tested population, independently of any variation of the viral prevalence over time. This and the fact that neither saliva nor nasopharyngeal sensitivities are affected in a screening-like context (the low prevalence being taken as a proxy, Figure S1 and S2) strongly predict that viral detection shall exhibit similar performance in both populations. Our meta-analysis showed large heterogeneity between studies. Sources of heterogeneity are both biological and technical. Biological heterogeneity may come from the fact that a given individual may carry the virus in only one of the saliva or is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint nasopharyngeal specimens, or from the timing of sampling during the course of contamination. Technical heterogeneity comes from differences in the sampling and in RT-PCR methods. Among the 49 studies meeting the inclusion criteria for the metaanalysis, 29 studies report saliva collection in sterile containers (urine tubes or vials) without any additional solution. The other studies diluted the saliva in various viral transport media or phosphate buffer saline with or without bovine serum albumin. Other sources of variability come from differences in the amplified region of SARS-Cov-2 or to different positivity threshold between studies; most studies do not present viral load data but only cycle thresholds (Ct) for specific amplification of SARS-Cov-2 sequences and not even Ct differences (ΔCt) with a human reference gene. Altogether, our meta-analysis of 49 studies including 16,272 paired samples shows high concordance (92.6%) between nasopharyngeal/oropharyngeal swabs and saliva, with a 5% higher sensitivity for the nasopharyngeal/orapharyngeal (92.2%) as compared to saliva (86.7%). While this might have been a liability in the context of individual diagnosis, this is not such a concern for mass screening, especially given the major advantage of the saliva sampling in terms of logistics. Previous meta-analyses of paired nasopharyngeal and saliva samples included less than 15 peer reviewed studies or preprints and reported average sensitivity of 91%, 85% and 83.4% in 4, 16 and 5 studies respectively [73] [74] [75] . However, these studies used nasopharyngeal positivity as the reference, which did not seem relevant in our context. To prevent a shortage of analytic reagents and to cut the costs necessarily associated to mass screening strategies, several recent publications have proposed mass testing methods based on saliva sampling either through extraction-free protocols [76] [77] [78] or through pre-extraction sample pooling [79] [80] [81] . In addition, sample pooling has gained a recognized interest for recurrent screening programs from the Centres of Disease Control recommendations 82 , and surveillance protocols implemented in higher education institutions across the world, e.g. the State University of New York (United States) 83 , Liège University (Belgium) 84 , Heidelberg University (Germany) 85 as well as at Nottingham University (United Kingdom) 86 . In conclusion, this meta-analysis conclusively demonstrates that saliva is as valid as nasopharyngeal sampling for the detection of SARS-CoV-2 infections in symptomatic as well as asymptomatic carriers. Contrarily to nasopharyngeal swabs, saliva sampling is simple, fast, non-invasive, inexpensive, painless and it thus uniquely applicable for surveillance, screening and diagnosis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint evidence/diagnostic-testing (accessed Jan. 4, 2021). 8. Detection of SASR-CoV-2 in saliva. https://www.has-sante.fr/jcms/p_3221176/fr/avis-n-2020-0081/ac/seap-du-27-novembre-2020-du-college-de-la-haute-autorite-de-sante-relatif-a-l-inscription-sur-laliste-des-actes-et-prestations-mentionnee-a-l-article-l-162-1-7-du-code-de-la-securite-sociale-de-l-acte-dedetection-du-genome-du-virus-sars-cov-2-par-technique-rt-lamp-integree-sur-prelevement-salivaire-systemeeasycov accessed Jan. 4, 2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint 3 studies meeting inclusion criteria found in reviews or just accepted. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint The confidence intervals for each study are computed using the Clopper-Pearson method. Those for the overall estimates (fixed-effect or random-effect) are based on normal approximation. The blue box size is proportional to the number of positive tests. The red line corresponds to the value of the overall concordance of the random-effect model. This vertical line enables to locate the studies having an estimate concordance higher than 92.6%. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint The confidence intervals for each study are computed using the Clopper-Pearson method. Those for the overall estimates (fixed-effect or random-effect) are based on normal approximation. The blue box size is proportional to the number of positive tests. The difference between fixed-effect or random-effect overall sensitivity (respectively 84.3%, 86.7%) is low. The red line corresponds to the value of the overall sensitivity of the random-effect model. This vertical line enables to locate the studies having an estimate sensitivity higher than 86.7%. The heterogeneity estimator I² is equal to 80%, which means a higher level of heterogeneity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint The confidence intervals for each study are computed using the Clopper-Pearson method. Those for the overall estimates (fixed-effect or random-effect) are based on the normal approximation. The blue box size is proportional to the number of positive tests. The red line corresponds to the value of the overall sensitivity of the random-effect model. This vertical line enables to locate the studies having an estimate sensitivity higher than 92.2%. The heterogeneity estimator I² is equal to 84%, which means a higher level of heterogeneity. . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251508 doi: medRxiv preprint Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo' Rapid Response to an Outbreak in Qingdao, China Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19 Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2 Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19 Saliva as an Alternative Specimen for Molecular COVID-19 Testing in Community Settings and Population-Based Screening Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence Saliva for use with a point of care assay for the rapid diagnosis of COVID-19 Evaluation of saliva as an alternative diagnostic specimen source for SARS-CoV-2 detection by RT-dPCR Comparison of saliva and nasopharyngeal swab SARS-CoV-2 RT-qPCR testing in a community setting Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2 Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2 Posterior oropharyngeal saliva for the detection of SARS-CoV-2 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2 Saliva is a Promising Alternative Specimen for the Detection of SARS-CoV-2 in Children and Adults Equivalent SARS-CoV-2 viral loads between nasopharyngeal swab and saliva in symptomatic patients Viral dynamics of SARS-CoV-2 in saliva from infected patients Salivary Detection of COVID-19 Posterior oropharyngeal salivafor the detection of SARS-CoV-2 SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity Mass screening of asymptomatic persons for SARS-CoV-2 using saliva SARS-CoV-2 Viral Load in Saliva Rises Gradually and to Moderate Levels in Some Humans Rethinking Covid-19 Test Sensitivity -A Strategy for Containment Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility Temporal dynamics in viral shedding and transmissibility of COVID-19 SARS-CoV-2: The viral shedding vs infectivity dilemma Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis Saliva-based testing for diagnosis of SARS-CoV-2 infection: A meta-analysis RT-qPCR assays based on saliva rather than on nasopharyngeal swabs are possible but should be interpreted with caution: results from a systematic review and meta-analysis Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA Extraction SalivaDirect: simple and sensitive molecular diagnostic test for SARS-Cov-2 surveillance Saliva as testing sample for SARS-CoV-2 detection by RT-PCR in low prevalence community setting Clinical validation of a sensitive test for saliva collected in healthcare and community settings with pooling utility for SARS-CoV-2 mass surveillance Pooling saliva to increase SARS-CoV-2 testing capacity New Corona testing strategies for the general public Pooled saliva samples for COVID-19 surveillance programme Appendix Figure S1 :